Erasca, Inc.

Erasca, Inc. is a clinical-stage precision oncology company focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its pipeline includes several investigational drugs: ERAS-0015, a pan-RAS molecular glue for RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for KRAS-mutated solid tumors; and ERAS-12, an EGFR D2/D3 biparatopic antibody for EGFR and RAS/MAPK solid tumors. The company also has partnerships to develop other candidates, such as naporafenib (from Novartis), ERAS-601 (from NiKang Therapeutics), and ERAS-007 (from Asana BioSciences). Erasca collaborates with Tango Therapeutics for clinical evaluation of ERAS-0015.

Erasca, Inc. is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol ERAS. Its shares are traded in US Dollars (USD), as the company is based in the United States. The exchange is a major US stock exchange, providing liquidity and visibility for the company's stock.

Erasca, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it focuses on developing innovative therapies for cancer, particularly those driven by the RAS/MAPK pathway. The company's work involves clinical-stage drug development, which includes research, preclinical studies, and clinical trials to bring new oncology treatments to patients.

Erasca, Inc. is headquartered in San Diego, California, United States. The company primarily serves the US market, as indicated by its region being 'us'. Its operations and clinical trials are likely focused in the US, although its partnerships with companies like Guangzhou Joyo Pharmatech (China) and Medshine Discovery (China) suggest some global collaboration. However, the company's core market and regulatory focus remain in the United States.

As a clinical-stage biotechnology company, Erasca, Inc. does not yet have approved products or commercial revenue. Its business model involves discovering and developing precision oncology therapies targeting the RAS/MAPK pathway. The company generates value through licensing agreements and collaborations with other pharmaceutical and biotech firms. For example, it has license agreements with Guangzhou Joyo Pharmatech for pan-RAS inhibitors, Medshine Discovery for pan-KRAS inhibitors, Novartis for naporafenib, NiKang Therapeutics for ERAS-601, and Asana BioSciences for ERAS-007. These partnerships may include upfront payments, milestone payments, and royalties on future sales. Additionally, Erasca has a clinical trial collaboration with Tango Therapeutics. The company's future revenue will depend on successful development and commercialization of its pipeline candidates.